Skip to main content

Safety and Tolerability of Lactobacillus reuteri DSM 17938 and Effects on Biomarkers in Healthy Adults: Results from a Randomized Masked Trial

  • 2012-09-06
  • PLoS ONE 7(9)
    • Nisha Mangalat
    • Yuying Liu
    • Nicole Y. Fatheree
    • M. Ferris
    • M. Arsdall
    • Zhongxue Chen
    • M. Rahbar
    • M. Rahbar
    • W. Gleason
    • J. Norori
    • D. Tran
    • J. M. Rhoads

Abstract

Background: There are few carefully-designed studies investigating the safety of individual probiotics approved under Investigational New Drug policies.

Objectives: The primary aim of this prospective, double-blind placebo-controlled trial was to investigate if daily treatment of adults with Lactobacillus reuteri DSM 17938 (LR) for 2 months is safe and well-tolerated. Our secondary aim was to determine if LR treatment has immune effects as determined by regulatory T cell percentages, expression of toll-like receptors (TLR)-2 and -4 on circulating peripheral blood mononuclear cells (PMBCs), cytokine expression by stimulated PBMC, and intestinal inflammation as measured by fecal calprotectin.

Methods: Forty healthy adults were randomized to a daily dose of 5 × 10(8) CFUs of LR (n = 30) or placebo (n = 10) for 2 months. Participants completed a daily diary card and had 7 clinic visits during treatment and observation.

Results: There were no severe adverse events (SAEs) and no significant differences in adverse events (AEs). There were no differences in PBMC subclasses, TLRs, or cytokine expression after treatment. The probiotic-treated group had a significantly higher fecal calprotectin level than the placebo group after 2 months of treatment: 50 µg/g (IQR 24-127 µg/g) vs. 17 µg/g (IQR 11-26 µg/g), p = 0.03, although values remained in the normal clinical range (0-162.9 µg/g). LR vials retained >10(8) CFUs viable organisms/ml.

Conclusions: LR is safe and well tolerated in adults, without significant changes in immunologic markers. There was a small but significant increase in fecal calprotectin, perhaps indicating some element of immune recognition at the intestinal level.

Trial registration: Clinical Trials.gov NCT00922727.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus reuteri DSM 17938Increased Fecal Calprotectin LevelsNeutral
Small
⬆ Back to top
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Receive updates about our products, services, sales, and special offers. Unsubscribe anytime. See our Privacy Policy for details on how we handle your information.

Join Our Community

Use support@pillser.com to get in touch.